Leon Chen - 16 Nov 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 16 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Nov 2022, 20:04:58 UTC
Prior SEC filing: 21 Jun 2022
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Frederic Chereau, as Attorney-in-Fact

Key filing fact

Leon Chen filed Form 4 for LogicBio Therapeutics, Inc. on 17 Nov 2022.

Key facts

This page summarizes Leon Chen's Form 4 filing for LogicBio Therapeutics, Inc..
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Nov 2022, 20:04.

Change

Previous filing in this sequence was filed on 21 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LOGC transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -22,333
Change %: -100%
Price
Shares after: 0
Date: 16 Nov 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LOGC transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -44,508
Change %: -100%
Price
Shares after: 0
Date: 16 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,508
Exercise price: $0.7300
Footnotes: F2, F3

LOGC transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -12,500
Change %: -100%
Price
Shares after: 0
Date: 16 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $0.3800
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Leon Chen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes.

Footnote F2

The options were fully vested as of June 19, 2021.

Footnote F3

At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.

Footnote F4

The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.